REVIEW ARTICLE


RAPID COMMUNICATIONS


In Vivo Efficacy of B43 (anti-CD19)-Pokeweed Antiviral Protein Immunotoxin Against Human Pre-B Cell Acute Lymphoblastic Leukemia in Mice With Severe Combined Immunodeficiency............ F.M. Uckun, C. Manivel, D. Arthur, L.M. Chelstrom, D. Finnegan, L. Tuel-Ahlgren, J.D. Irvin, D.E. Myers, and R. Gunther

Tyrosine Phosphorylation of rasGAP and Associated Proteins in Chronic Myelogenous Leukemia Cell Lines B. Druker, K. Okuda, U. Matulonis, R. Salgia, T. Roberts, and J.D. Griffin

Demonstration of Stem Cell Inhibition and Myeloprotective Effects of SCI/rhMIP1α In Vivo.............. D.J. Dunlop, E.G. Wright, S. Lorimore, G.J. Graham, T. Holyoke, D.J. Kerr, S.D. Wolfe, and J.B. Pragnell

Protein Disulfide Isomerase Activity Is Released by Activated Platelets.............. K. Chen, Y. Lin, and T.C. Detwiler

CLINICAL INTERVENTION AND THERAPEUTIC TRIALS


HEMATOPOIESIS

Hematopoietic Growth Factors Released by Marrow Stromal Cells From Patients With Aplastic Anemia S. Kojima, T. Matsuyama, and Y. Kodera

Tumor Necrosis Factor Stimulates Na+/H+ Antiporter in Human Fibroblasts: Dissociation Between Intracellular Alkalization and Cytokine mRNA Accumulation.. Y.Y. Lee, I. Kurtz, K. Yamato, Z. El-Hajjouj, and H.P. Koeffler


Ineffective Hematopoiesis in Folate-Deficient Mice.............. N.D. Bills, M.J. Koury, A.J. Clifford, and E.N. Dessypris

(Continued on following page)
Colony-forming Unit-Granulocyte-Macrophage and DNA Synthesis of Human Bone Marrow Are Circadian
Stage-dependent and Show Covariation
R. Smaaland, O.D. Laerum, R.B. Sothern, O. Sletvold, R. Bjerknes, and K. Lote

Two Types of Murine CD34 mRNA Generated by Alternative Splicing
J. Suda, T. Sudo, M. Ito, N. Ohno, Y. Yamaguchi, and T. Suda

Isolation and Molecular Characterization of the Human CD34 Gene
X-Y. He, KP. Antao, D. Basila, J.C. Marx, and B.R. Davis

HEMOSTASIS AND THROMBOSIS

The Arg-Gly-Asp (RGD) Recognition Site of Platelet Glycoprotein IIb-IIIa on Nonactivated Platelets Is
Accessible to High-Affinity Macromolecules
Y. Tomiyama, T. Tsubakio, R.S. Piotrowicz, Y. Kurata, J.C. Loftus, and T.J. Kunicki

Binding of Fibrin Fragments to One-Chain and Two-Chain Tissue-Type Plasminogen Activator
A.A.K. Hasan, W.S. Chang, and A.Z. Budzynski

Thrombolytic and Pharmacokinetic Properties of an Immunoconjugate of Single-Chain Urokinase-Type
Plasminogen Activator (u-PA) and a Bispecific Monoclonal Antibody Against Fibrin and Against u-PA in
Baboons
Y. Imura, J.M. Stassen, T. Kurokawa, S. Iwasa, H.R. Lijnen, and D. Collen

Molecular Cloning and Expression of Rabbit Antithrombin III
W.P. Sheffield, A.B. Brothers, M.J. Wells, M.W.C. Hatton, B.J. Clarke, and M.A. Blajchman

Direct Detection of Activated Protein C in Blood From Human Subjects
A. Gruber and J.H. Griffin

Preferred Sequence Requirements for Cleavage of Pro-von Willebrand Factor by Propeptide-Processing
Enzymes
A. Rehemtulla and R.J. Kaufman

IMMUNOBIOLOGY

Effect of Interleukin-1 (IL-1) Blockade on Cytokine Synthesis: I. IL-1 Receptor Antagonist Inhibits
IL-1–Induced Cytokine Synthesis and Blocks the Binding of IL-1 to Its Type II Receptor on Human
Monocytes
E.V. Granowitz, B.D. Clark, E. Vannier, M.V. Callahan, and C.A. Dinarello

Effect of Interleukin-1 (IL-1) Blockade on Cytokine Synthesis: II. IL-1 Receptor Antagonist Inhibits
Lipopolysaccharide-Induced Cytokine Synthesis by Human Monocytes

NEOPLASIA

Bone Marrow-Derived Stromal Cells Prevent Apoptotic Cell Death in B-Lineage Acute Lymphoblastic
Leukemia
A. Manabe, E. Coustan-Smith, F.G. Behm, S.C. Raimondi, and D. Campana

Frequent Mutations in the p53 Gene in Human Myeloid Leukemia Cell Lines

Isochromosomes in Childhood Acute Lymphoblastic Leukemia: A Collaborative Study of 83 Cases
F.G. Behm, C.P. Steuber, and V.J. Land

Antitumor Effects of Human Recombinant Interleukin-6 on Acute Myeloid Leukemia in Mice and in Cell
Cultures
T. Givon, S. Slavin, N. Haran-Ghera, R. Michalevitz, and M. Revel

False-Positive Flow Cytometric Platelet Glycoprotein IIb/IIIa Expression in Myeloid Leukemias Secondary to
Platelet Adherence to Blasts
S.A. Betz, K. Foucar, D.R. Head, I.-M. Chen, and C.L. Willman

Dissociation of Nuclear Events On p21 RAS Transformation of FDC-P1 Myeloid Cells: c-jun/AP-1 Expression
Versus c-myc Transcription
S. Litz-Jackson, A.H. Miller, G.S. Burgess, and H.S. Boswell

(Continued on following page)


PHAGOCYTES

Reconstitution of Defective Respiratory Burst Activity With Partially Purified Human Neutrophil Cytochrome B in Two Genetic Forms of Chronic Granulomatous Disease: Possible Role of Rap1A ..................M.T. Quinn, J.T. Curnutte, C.A. Parkos, M.L. Mullen, P.I. Scott, R.W. Erickson, and A.J. Jesaitis

Granulocyte-Macrophage Colony-Stimulating Factor Induces a Staurosporine Inhibitable Tyrosine Phosphorylation of Unique Neutrophil Proteins..........................................................R.L. Berkow

RED CELLS

A Deletion/Inversion Rearrangement of the β-Globin Gene Cluster in a Turkish Family With β-thalassemia Intermedia..................................................A.E. Kulozik, A. Bellan-Koch, E. Kohn, and E. Kleihauer

Reduced Deformability of Thalassemic Erythrocytes and Erythrocytes With Abnormal Hemoglobins and Relation With Susceptibility to Plasmodium falciparum Invasion..........A. Bunyaarev, P. Buttpeer, N. Sae-Ung, S. Fucharoen, and Y. Yuthavong


Developmental Switch in the Relative Expression of the α1- and α2-Globin Genes in Humans and in Transgenic Mice........................................................................M. Albitar, F.E. Cash, C. Peschle, and S.A. Liebhaber

TRANSPLANTATION

Is 600 mg/m2 the Appropriate Dosage of Busulfan in Children Undergoing Bone Marrow Transplantation? G. Vassal, A. Deroussenti, D. Challine, O. Hartmann, S. Koscielny, D. Valteau-Couanet, J. Lemerle, and A. Gouyette

TRANSFUSION MEDICINE

Thrombocytopenia Caused By Passive Transfusion of Anti-Glycoprotein Ia/IIa Alloantibody (Anti–HPA-5b) T.E. Warkentin, J.W. Smith, C.P.M. Hayward, A.M. Ali, and J.G. Kelton


CORRESPONDENCE

Pharmacology and Mechanism of Action of Ancrod: Potential for Inducing Thrombosis.................................................................2492

Cure in Acute Promyelocytic Leukemia: Now More Readily Achievable With Less Toxic Therapy ........................2492


Bleeding Time Revisited ..............................................................................................................................................2495

Lack of Apparent Hematologic Abnormalities in Human Patients With c-kit (stem cell factor receptor) Gene Mutations ..........................................................................................................................2497

(Continued on following page)
CONTENTS (Contents continued)

BCR-ABL Breakpoint and Prognosis in Chronic Myeloid Leukemia ................................................................. 2499
Macrophage Colony-Stimulating Factor Is Produced by Activated T Lymphocytes In Vitro and Is Detected In Vivo in T Cells From Reactive Lymph Nodes ................................................................. 2500

SPECIAL DEPARTMENTS
Announcements .......................................................................................................................................................... 2502
Information for Contributors .................................................................................................................................... xl

All manuscripts submitted to BLOOD and subsequently accepted for publication will be assessed a $50.00 charge per published page. This charge is necessary to offset the increasing costs of publication.

All manuscripts submitted for consideration for publication in BLOOD should be sent to: Arthur W. Nienhuis, M.D., Editor, BLOOD, The Journal of the American Society of Hematology, 9650 Rockville Pike, Bethesda, MD 20814. For other information, call (301) 571-1895.

The American Society of Hematology certifies that the continuing medical education offering provided by BLOOD, The Journal of The American Society of Hematology, meets the criteria for up to 22 hours of credit in Category 5(a) for the Physician’s Recognition Award of the American Medical Association.
